[Hinews] SEOUL, South Korea — Caregen, a South Korean biotech company specializing in peptide therapeutics, announced on July 30 that its weight-management peptide, Korglutide, has been officially approved as a health supplement by Indian health authorities.

This regulatory milestone paves the way for Caregen to distribute and commercialize Korglutide in India, one of the world’s fastest-growing health and wellness markets. Korglutide, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, offers a competitive edge over injectable GLP-1 therapies by providing user convenience and helping to preserve lean muscle mass during weight reduction.

In a 12-week clinical trial conducted in India, Korglutide demonstrated notable efficacy, with participants achieving an average body weight reduction of 10.8%. The trial also found that the weight loss was primarily attributable to reductions in body fat, with no reported cases of treatment discontinuation—highlighting Korglutide’s favorable safety and tolerability profile.

Illustration of Korglutide’s mechanism of action in promoting weight management. (Image courtesy of Caregen)
Illustration of Korglutide’s mechanism of action in promoting weight management. (Image courtesy of Caregen)

Amid growing concerns over side effects linked to injectable GLP-1 therapies, Korglutide is emerging as a promising oral alternative. Caregen plans to introduce the peptide in various formulations, including oral powders and dissolvable films, and is collaborating with major Indian pharmaceutical firms to broaden its distribution network.

“Korglutide represents a next-generation weight management solution, integrating advanced peptide technology with a robust safety profile,” said Yongji Chung, CEO of Caregen. “We believe it will quickly gain traction in India’s premium health market.”

키워드

#케어젠#체중감량#펩타이드#코글루타이드
저작권자 © Hinews 무단전재 및 재배포 금지
ad